A PDX model stands for patient-derived xenograft.
That means in the oncology space that
patient tissue, normally tumor,
is transplanted from a human patient
into a mouse to maintain as a model.
In recent years there were multiple efforts
to establish and characterize large PDX collections.
Although these models are available
for a number of decades since the 1980s,
their advantages have become more and more important
for drug development and tumor biology research.
The main advantages of PDX models
are that they maintain their genetic heterogeneity
as well as the histological makeup of the patient
and preserve them over the passages.
This gives them the possibility to cover
all different histotypes from a specific disease.
Charles River offers a great PDX collection
covering more than 500 different models,
including all different entities like the broad models,
like non-small cell lung cancer, breast cancer,
or colon cancer,
but as well, tumor models with a high medical need
like ovarian cancer, acute myeloid leukemia,
non-Hodgkin lymphoma or prostate cancer.
The PDX models in the Charles River compendium
are characterized with molecular techniques
like whole-exome sequencing and RNA-seq.
We also have patient metadata available
as well as histology and immunohistochemistry data
and sensitivity toward standard of care treatments.
With the advent of new modalities,
like for example, immuno-oncology,
we tried to enhance our PDX models
by analyzing them also in a humanized setting.
For example, we analyzed the rates
of tumor-infiltrating lymphocytes,
as well as sensitivity toward checkpoint inhibitors.
PDX models are an important part of the preclinical toolbox
because they are complementary to the gold standard models
like cell line graft models,
syngeneic, or genetic modified mouse models.